These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases. Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561 [TBL] [Abstract][Full Text] [Related]
3. The molecular pathogenesis of craniopharyngiomas. Campanini ML; Almeida JP; Martins CS; de Castro M Arch Endocrinol Metab; 2023 Mar; 67(2):266-275. PubMed ID: 36748936 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma? Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631 [TBL] [Abstract][Full Text] [Related]
5. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression. Apps JR; Gonzalez-Meljem JM; Guiho R; Pickles JC; Prince E; Schwalbe E; Joshi N; Stone TJ; Ogunbiyi O; Chalker J; Bassey A; Otto G; Davies R; Hughes D; Brandner S; Tan E; Lee V; Hayhurst C; Kline C; Castellano S; Hankinson T; Deutschbein T; Jacques TS; Martinez-Barbera JP Acta Neuropathol Commun; 2024 Aug; 12(1):127. PubMed ID: 39127699 [TBL] [Abstract][Full Text] [Related]
7. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma]. Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087 [No Abstract] [Full Text] [Related]
8. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas. Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946 [TBL] [Abstract][Full Text] [Related]
9. The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis. Preda V; Larkin SJ; Karavitaki N; Ansorge O; Grossman AB Endocr Pathol; 2015 Mar; 26(1):1-8. PubMed ID: 25355426 [TBL] [Abstract][Full Text] [Related]
10. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929 [TBL] [Abstract][Full Text] [Related]
11. Pathology and pathogenesis of craniopharyngiomas. Larkin SJ; Ansorge O Pituitary; 2013 Mar; 16(1):9-17. PubMed ID: 22886701 [TBL] [Abstract][Full Text] [Related]
12. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing. He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552 [TBL] [Abstract][Full Text] [Related]
13. Targeted therapies in the medical management of craniopharyngioma. Iglesias P Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645 [TBL] [Abstract][Full Text] [Related]
14. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918 [TBL] [Abstract][Full Text] [Related]
15. 60 YEARS OF NEUROENDOCRINOLOGY: Biology of human craniopharyngioma: lessons from mouse models. Martinez-Barbera JP J Endocrinol; 2015 Aug; 226(2):T161-72. PubMed ID: 25926515 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813 [TBL] [Abstract][Full Text] [Related]
18. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas. Esheba GE; Hassan AA J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262 [TBL] [Abstract][Full Text] [Related]
19. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes]. Fujio S; Hanaya R No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344 [TBL] [Abstract][Full Text] [Related]
20. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology. Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]